


This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently Amended) A compound of Formula I:



I

in which:

X^1 is $\text{-NHC(R}^1\text{)(R}^2\text{)X}^3$ or -NHX^4 ;

X^2 is morpholin-4-ylcarbonyloxy hydrogen, fluoro, -OH , -OR^4 , -NHR^{15} or $\text{-NR}^{17}\text{R}^{18}$ and

X^7 is hydrogen or X^2 and X^7 both represent fluoro;

X^3 is benzooxazol-2-ylcarbonyl cyano, $\text{-C(R}^7\text{)(R}^8\text{)R}^{16}$, $\text{-C(R}^6\text{)(OR}^6\text{)}_2$, $\text{-CH}_2\text{C(O)R}^{16}$, $\text{-CH=CHS(O)}_2\text{R}^5$, $\text{-C(O)CF}_2\text{C(O)NR}^5\text{R}^5$, $\text{-C(O)C(O)NR}^5\text{R}^6$, -C(O)C(O)OR^5 , $\text{-C(O)CH}_2\text{OR}^5$, $\text{-C(O)CH}_2\text{N(R}^6\text{)SO}_2\text{R}^5$ or -C(O)C(O)R^5 ; wherein R^5 is hydrogen, (C_{1-4}) alkyl, (C_{3-10}) cycloalkyl, (C_{0-6}) alkyl, hetero (C_{3-10}) cycloalkyl, (C_{0-3}) alkyl, (C_{6-10}) aryl, (C_{0-6}) alkyl, hetero (C_{5-10}) aryl, (C_{0-6}) alkyl, (C_{9-10}) bicycloaryl, (C_{0-6}) alkyl or hetero (C_{8-10}) bicycloaryl, (C_{0-6}) alkyl; R^6 is hydrogen, hydroxy or (C_{1-6}) alkyl; or where X^3 contains an $\text{-NR}^5\text{R}^6$ group, R^5 and R^6 together with the nitrogen atom to which they are both attached, form hetero (C_{3-10}) cycloalkyl, hetero (C_{5-10}) aryl or hetero (C_{8-10}) bicycloaryl; R^7 is hydrogen or (C_{1-4}) alkyl and R^8 is hydroxy or R^7 and R^8 together form oxo; R^{16} is hydrogen, -X^4 , -CF_3 , $\text{-CF}_2\text{CF}_2\text{R}^9$ or $\text{-N(R}^6\text{)OR}^6$; R^9 is hydrogen, halo, (C_{1-4}) alkyl,

~~(C₅₋₁₀)aryl(C₀₋₆)alkyl or (C₅₋₁₀)heteroaryl(C₀₋₆)alkyl, with the proviso that when X³ is cyano, then X² is hydrogen, fluoro, OH, OR⁴ or NR¹⁷R¹⁸ and X⁷ is hydrogen or X² and X⁷ both represent fluoro;~~

~~X⁴ is a heteromonocyclic ring containing 4 to 7 ring member atoms or a fused heterobicyclic ring system containing 8 to 14 ring member atoms and any carbocyclic ketone, iminoketone or thioketone derivative thereof, with the proviso that when X⁴ is other than a heteromonocyclic ring containing 5 ring member atoms, wherein no more than two of the ring member atoms comprising the ring are heteroatoms, then X² is fluoro, OH, OR⁴, NHR¹⁵ or NR¹⁷R¹⁸ and X⁷ is hydrogen or X² and X⁷ both represent fluoro;~~

wherein within R⁵, X³ or X⁴ any alicyclic or aromatic ring system is unsubstituted or substituted further by 1 to 5 radicals independently selected from (C₁₋₆)alkyl, (C₁₋₆)alkylidene, cyano, halo, halo-substituted(C₁₋₄)alkyl, nitro, -X⁵NR¹²R¹², -X⁵NR¹²C(O)R¹², -X⁵NR¹²C(O)OR¹², -X⁵NR¹²C(O)NR¹²R¹², -X⁵NR¹²C(NR¹²)NR¹²R¹², -X⁵OR¹², -X⁵SR¹², -X⁵C(O)OR¹², -X⁵C(O)R¹², -X⁵OC(O)R¹², -X⁵C(O)NR¹²R¹², -X⁵S(O)₂NR¹²R¹², -X⁵NR¹²S(O)₂R¹², -X⁵P(O)(OR¹²)OR¹², -X⁵OP(O)(OR¹²)OR¹², -X⁵NR¹²C(O)R¹³, -X⁵S(O)R¹³ and -X⁵S(O)₂R¹³ and/or 1 radical selected from -R¹⁴, -X⁵OR¹⁴, -X⁵SR¹⁴, -X⁵S(O)R¹⁴, -X⁵S(O)₂R¹⁴, -X⁵C(O)R¹⁴, -X⁵C(O)OR¹⁴, -X⁵OC(O)R¹⁴, -X⁵NR¹⁴R¹², -X⁵NR¹²C(O)R¹⁴, -X⁵NR¹²C(O)OR¹⁴, -X⁵C(O)NR¹²R¹², -X⁵S(O)₂NR¹⁴R¹², -X⁵NR¹²S(O)₂R¹⁴, -X⁵NR¹²C(O)NR¹⁴R¹² and -X⁵NR¹²C(NR¹²)NR¹⁴R¹², wherein X⁵ is a bond or (C₁₋₆)alkylene;

R¹² at each occurrence independently is hydrogen, ~~(C₁₋₅)alkyl~~ ~~(C₁₋₆)alkyl~~ or halo-substituted(C₁₋₆)alkyl;

R¹³ is (C₁₋₆)alkyl or halo-substituted(C₁₋₆)alkyl; and

R¹⁴ is (C₃₋₁₀)cycloalkyl(C₀₋₆)alkyl, ~~hetero(C₃₋₁₀)cycloalkyl(C₀₋₃)alkyl,~~ (C₆₋₁₀)aryl(C₀₋₆)alkyl, ~~hetero(C₅₋₁₀)aryl(C₀₋₆)alkyl,~~ or (C₉₋₁₀)bicycloaryl(C₀₋₆)alkyl or ~~hetero(C₈₋₁₀)bicycloaryl(C₀₋₆)alkyl;~~

R^1 is hydrogen or (C_{1-6}) alkyl and R^2 is selected from a group consisting of hydrogen, cyano, $-X^5NR^{12}R^{12}$, $-X^5NR^{12}C(O)R^{12}$, $-X^5NR^{12}C(O)OR^{12}$, $-R^{12}$, $-X^5NR^{12}C(O)NR^{12}R^{12}$, $-X^5NR^{12}C(NR^{12})NR^{12}R^{12}$, $-X^5OR^{12}$, $-X^5SR^{12}$, $-X^5C(O)OR^{12}$, $-X^5C(O)R^{12}$, $-X^5OC(O)R^{12}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{12}R^{12}$, $-X^5NR^{12}S(O)_2R^{12}$, $-X^5P(O)(OR^{12})OR^{12}$, $-X^5OP(O)(OR^{12})OR^{12}$, $-X^5NR^{12}C(O)R^{13}$, $-X^5S(O)R^{13}$, $-X^5S(O)_2R^{13}$, $-R^{14}$, $-X^5OR^{14}$, $-X^5SR^{14}$, $-X^5S(O)R^{14}$, $-X^5S(O)_2R^{14}$, $-X^5C(O)R^{14}$, $-X^5C(O)OR^{14}$, $-X^5OC(O)R^{14}$, $-X^5NR^{14}R^{12}$, $-X^5NR^{12}C(O)R^{14}$, $-X^5NR^{12}C(O)OR^{14}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{14}R^{12}$, $-X^5NR^{12}S(O)_2R^{14}$, $-X^5NR^{12}C(O)NR^{14}R^{12}$ and $-X^5NR^{12}C(NR^{12})NR^{14}R^{12}$, wherein X^5 , R^{12} , R^{13} and R^{14} are as defined above; ~~or R^1 and R^2 taken together with the carbon atom to which both R^1 and R^2 are attached form (C_{3-8}) cycloalkylene or (C_{3-8}) heterocycloalkylene; wherein within said R^2 any heteroaryl, aryl, cycloalkyl, heterocycloalkyl, cycloalkylene or heterocycloalkylene is unsubstituted or substituted with 1 to 3 radicals independently selected from (C_{1-6}) alkyl, (C_{1-6}) alkylidene, cyano, halo, halo-substituted (C_{1-4}) alkyl, nitro, $-X^5NR^{12}R^{12}$, $-X^5NR^{12}C(O)R^{12}$, $-X^5NR^{12}C(O)OR^{12}$, $-X^5NR^{12}C(O)NR^{12}R^{12}$, $-X^5NR^{12}C(NR^{12})NR^{12}R^{12}$, $-X^5OR^{12}$, $-X^5SR^{12}$, $-X^5C(O)OR^{12}$, $-X^5C(O)R^{12}$, $-X^5OC(O)R^{12}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{12}R^{12}$, $-X^5NR^{12}S(O)_2R^{12}$, $-X^5P(O)(OR^{12})OR^{12}$, $-X^5OP(O)(OR^{12})OR^{12}$, $-X^5NR^{12}C(O)R^{13}$, $-X^5S(O)R^{13}$, $-X^5S(O)_2R^{13}$ and $-X^5C(O)R^{13}$, wherein X^5 , R^{12} and R^{13} are as defined above;~~

R^3 is (C_{1-6}) alkyl or $-C(R^6)(R^6)X^6$, wherein R^6 is hydrogen or (C_{1-6}) alkyl and X^6 is selected from $-X^5NR^{12}R^{12}$, $-X^5NR^{12}C(O)R^{12}$, $-X^5NR^{12}C(O)OR^{12}$, $-X^5NR^{12}C(O)NR^{12}R^{12}$, $-X^5NR^{12}C(NR^{12})NR^{12}R^{12}$, $-X^5OR^{12}$, $-X^5SR^{12}$, $-X^5C(O)OR^{12}$, $-X^5C(O)R^{12}$, $-X^5OC(O)R^{12}$, $-X^5C(O)NR^{12}R^{12}$, $-X^5S(O)_2NR^{12}R^{12}$, $-X^5NR^{12}S(O)_2R^{12}$, $-X^5P(O)(OR^{12})OR^{12}$, $-X^5OP(O)(OR^{12})OR^{12}$, $-X^5C(O)R^{13}$, $-X^5NR^{12}C(O)R^{13}$, $-X^5S(O)R^{13}$, $-X^5S(O)_2R^{13}$, $-R^{14}$, $-X^5OR^{14}$, $-X^5SR^{14}$, $-X^5S(O)R^{14}$, $-X^5S(O)_2R^{14}$, $-X^5C(O)R^{14}$, $-X^5C(O)OR^{14}$, $-X^5OC(O)R^{14}$, $-X^5NR^{14}R^{12}$, $-X^5NR^{12}C(O)R^{14}$, $-X^5NR^{12}C(O)OR^{14}$, $-X^5C(O)NR^{14}R^{12}$, $-X^5S(O)_2NR^{14}R^{12}$, $-X^5NR^{12}S(O)_2R^{14}$, $-X^5NR^{12}C(O)NR^{14}R^{12}$ and $-X^5NR^{12}C(NR^{12})NR^{14}R^{12}$ wherein X^5 , R^{12} , R^{13} and R^{14} are as defined above;

~~R⁴ is selected from X⁸NR¹²R¹², X⁸NR¹²C(O)R¹², X⁸NR¹²C(O)OR¹²,
X⁸NR¹²C(O)NR¹²R¹², X⁸NR¹²C(NR¹²)NR¹²R¹², X⁸OR¹², X⁸SR¹², X⁵C(O)OR¹²,
X⁵C(O)R¹², X⁸OC(O)R¹², X⁵C(O)NR¹²R¹², X⁸S(O)₂NR¹²R¹², X⁸NR¹²S(O)₂R¹²,
X⁸P(O)(OR¹²)OR¹², X⁸OP(O)(OR¹²)OR¹², X⁵C(O)R¹³, X⁸NR¹²C(O)R¹³, X⁸S(O)R¹³,
X⁸S(O)₂R¹³, R¹⁴, X⁸OR¹⁴, X⁸SR¹⁴, X⁸S(O)R¹⁴, X⁸S(O)₂R¹⁴, X⁵C(O)R¹⁴,
X⁵C(O)OR¹⁴, X⁸OC(O)R¹⁴, X⁸NR¹⁴R¹², X⁸NR¹²C(O)R¹⁴, X⁸NR¹²C(O)OR¹⁴,
X⁵C(O)NR¹⁴R¹², X⁸S(O)₂NR¹⁴R¹², X⁸NR¹²S(O)₂R¹⁴, X⁸NR¹²C(O)NR¹⁴R¹² and
X⁸NR¹²C(NR¹²)NR¹⁴R¹² wherein X⁸ is (C₁₋₆)alkylene and X⁵, R¹², R¹³ and R¹⁴ are as
defined above, with the proviso that when X³ is cyano and X² is OR⁴, where R⁴ is
defined as R¹⁴, then R¹⁴ is (C₃₋₁₀)cycloalkyl(C₁₋₆)alkyl, hetero(C₃₋₁₀)cycloalkyl(C₁₋₃)alkyl,
(C₆₋₁₀)aryl(C₁₋₆)alkyl, hetero(C₅₋₁₀)aryl(C₁₋₆)alkyl, (C₉₋₁₀)bicycloaryl(C₁₋₆)alkyl or
hetero(C₈₋₁₀)bicycloaryl(C₁₋₆)alkyl;~~

~~R¹⁵ is (C₆₋₁₀)aryl, hetero(C₅₋₁₀)aryl, (C₉₋₁₀)bicycloaryl or hetero(C₈₋₁₀)bicycloaryl;~~

~~R¹⁷ is (C₁₋₆)alkyl, (C₃₋₁₀)cycloalkyl(C₀₋₆)alkyl, hetero(C₃₋₁₀)cycloalkyl(C₀₋₃)alkyl,
(C₆₋₁₀)aryl(C₀₋₆)alkyl, hetero(C₅₋₁₀)aryl(C₀₋₆)alkyl, (C₉₋₁₀)bicycloaryl(C₀₋₆)alkyl or
hetero(C₈₋₁₀)bicycloaryl(C₀₋₆)alkyl, with the proviso that when X³ is cyano, then R¹⁷ is
(C₁₋₆)alkyl, (C₃₋₁₀)cycloalkyl(C₁₋₆)alkyl, hetero(C₃₋₁₀)cycloalkyl(C₁₋₆)alkyl,
(C₆₋₁₀)aryl(C₁₋₆)alkyl, hetero(C₅₋₁₀)aryl(C₁₋₆)alkyl, (C₉₋₁₀)bicycloaryl(C₁₋₆)alkyl or
hetero(C₈₋₁₀)bicycloaryl(C₁₋₆)alkyl;~~

~~R¹⁸ is hydrogen, (C₁₋₆)alkyl, (C₃₋₁₀)cycloalkyl(C₀₋₆)alkyl,
hetero(C₃₋₁₀)cycloalkyl(C₀₋₆)alkyl, (C₆₋₁₀)aryl(C₀₋₆)alkyl, hetero(C₅₋₁₀)aryl(C₀₋₆)alkyl,
(C₉₋₁₀)bicycloaryl(C₀₋₆)alkyl or hetero(C₈₋₁₀)bicycloaryl(C₀₋₆)alkyl, with the proviso that
when X³ is cyano, then R¹⁸ is (C₁₋₆)alkyl, (C₃₋₁₀)cycloalkyl(C₁₋₆)alkyl,
hetero(C₃₋₁₀)cycloalkyl(C₁₋₆)alkyl, (C₆₋₁₀)aryl(C₁₋₆)alkyl, hetero(C₅₋₁₀)aryl(C₁₋₆)alkyl,
(C₉₋₁₀)bicycloaryl(C₁₋₆)alkyl or hetero(C₈₋₁₀)bicycloaryl(C₁₋₆)alkyl; and~~

wherein within R³, R⁴, R¹⁵, R¹⁷ and R¹⁸ any aliphatic or aromatic ring system is
unsubstituted or substituted further by 1 to 5 radicals independently selected from

(C₁₋₆)alkyl, (C₁₋₆)alkylidene, cyano, halo, halo-substituted(C₁₋₄)alkyl, nitro, -X⁵NR¹²R¹², -X⁵NR¹²C(O)R¹², -X⁵NR¹²C(O)OR¹², -X⁵NR¹²C(O)NR¹²R¹², -X⁵NR¹²C(NR¹²)NR¹²R¹², -X⁵OR¹², -X⁵SR¹², -X⁵C(O)OR¹², -X⁵C(O)R¹², -X⁵OC(O)R¹², -X⁵C(O)NR¹²R¹², -X⁵S(O)₂NR¹²R¹², -X⁵NR¹²S(O)₂R¹², -X⁵P(O)(OR¹²)OR¹², -X⁵OP(O)(OR¹²)OR¹², -X⁵NR¹²C(O)R¹³, -X⁵S(O)R¹³, -X⁵C(O)R¹³ and -X⁵S(O)₂R¹³ and/or 1 radical selected from -R¹⁴, -X⁵OR¹⁴, -X⁵SR¹⁴, -X⁵S(O)R¹⁴, -X⁵S(O)₂R¹⁴, -X⁵C(O)R¹⁴, -X⁵C(O)OR¹⁴, -X⁵OC(O)R¹⁴, -X⁵NR¹⁴R¹², -X⁵NR¹²C(O)R¹⁴, -X⁵NR¹²C(O)OR¹⁴, -X⁵C(O)NR¹⁴R¹², -X⁵S(O)₂NR¹⁴R¹², -X⁵NR¹²S(O)₂R¹⁴, -X⁵NR¹²C(O)NR¹⁴R¹² and -X⁵NR¹²C(NR¹²)NR¹⁴R¹²; and within R³ and R⁴ any aliphatic moiety is unsubstituted or substituted further by 1 to 5 radicals independently selected from cyano, halo, nitro, -NR¹²R¹², -NR¹²C(O)R¹², -NR¹²C(O)OR¹², -NR¹²C(O)NR¹²R¹², -NR¹²C(NR¹²)NR¹²R¹², -OR¹², -SR¹², -C(O)OR¹², -C(O)R¹², -OC(O)R¹², -C(O)NR¹²R¹², -S(O)₂NR¹²R¹², -NR¹²S(O)₂R¹², -P(O)(OR¹²)OR¹², -OP(O)(OR¹²)OR¹², -NR¹²C(O)R¹³, -S(O)R¹³ and -S(O)₂R¹³; wherein X⁵, R¹², R¹³ and R¹⁴ are as described above, ~~with the proviso that when X³ is cyano and X² is -OR⁴, where R⁴ is defined as -R¹⁴, or -NHR¹⁸, then any aromatic ring system present within R¹⁴ or R¹⁸ is not substituted further by halo,~~ (C₃₋₁₀)cycloalkyl, hetero(C₃₋₁₀)cycloalkyl, (C₆₋₁₀)aryl, hetero(C₅₋₁₀)aryl, (C₉₋₁₀)bicycloaryl or hetero(C₈₋₁₀)bicycloaryl; with the proviso that only one bicyclic ring structure is present within R³, R⁴ or R¹⁵; and the pharmaceutically acceptable salts and solvates of such compounds and the *N*-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and mixtures of stereoisomers thereof.

2-7. (Cancelled)

8. (Currently Amended) The compound of Claim 1[[3]] in which:

~~X¹ is -NHC(R¹)(R²)X³ or -NHCH(R¹⁹)C(O)R²⁰, wherein R¹ is hydrogen or (C₁₋₆)alkyl and R² is hydrogen, (C₁₋₆)alkyl, -X⁵OR¹², -X⁵S(O)R¹³, -X⁵OR¹⁴, (C₆₋₁₀)aryl, (C₀₋₆)alkyl or~~

~~hetero(C₅₋₁₀)aryl(C₀₋₆)alkyl or R¹ and R² taken together with the carbon atom to which both R¹ and R² are attached form (C₃₋₆)cycloalkylene or (C₃₋₆)heterocycloalkylene, wherein within said R² any heteroaryl, aryl, cycloalkylene or heterocycloalkylene is unsubstituted or substituted with (C₁₋₆)alkyl or hydroxy, wherein X³ is cyano, C(O)R¹⁶, C(R⁶)(OR⁶)₂, CH=CHS(O)₂R⁵, CH₂C(O)R¹⁶, C(O)CF₂C(O)NR⁵R⁵, C(O)C(O)NR⁵R⁶, C(O)C(O)OR⁵, C(O)CH₂OR⁵, C(O)CH₂N(R⁶)SO₂R⁵ or C(O)C(O)R⁵ and R¹⁹ and R²⁰ together with the atoms to which R¹⁹ and R²⁰ are attached form (C₄₋₈)heterocycloalkylene, wherein no more than one of the ring member atoms comprising the ring is a heteroatom selected from NR²¹ or O, wherein the ring is unsubstituted or substituted with (C₁₋₆)alkyl or X⁵C(O)OR¹² and R²¹ is hydrogen, (C₁₋₆)alkyl, X⁵C(O)R¹², X⁵C(O)OR¹², R¹⁴, X⁵C(O)R¹⁴ or C(O)OR¹⁴;~~

~~X² is OH or OC(O)NR¹²R¹², wherein each R¹² independently represent hydrogen or (C₁₋₆)alkyl, wherein said alkyl is unsubstituted or substituted with hydroxy or methoxy, or X² is OC(O)NHR¹⁴, wherein R¹⁴ is (C₃₋₁₀)cycloalkyl(C₀₋₆)alkyl or hetero(C₃₋₁₀)cycloalkyl(C₁₋₃)alkyl, or X² is OC(O)R¹⁴, wherein R¹⁴ is NR²²R²³ and R²² and R²³ together with the nitrogen atom to which both R²² and R²³ attached form a hetero(C₄₋₆)cycloalkyl ring, which ring may be unsubstituted or substituted with hydroxy;~~
and

~~R³ is -CH₂X⁶; wherein X⁶ is selected from X⁵SR¹², X⁵C(O)NR¹²R¹², X⁵S(O)₂R¹³, X⁵C(O)R¹³, X⁵OR¹², X⁵SR¹⁴, X⁵R¹⁴, X⁵S(O)₂R¹⁴, X⁵C(O)R¹⁴, X⁵C(O)NR¹⁴R¹²; and~~
or the pharmaceutically acceptable salts and or solvates of such compounds and or the N-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and or mixtures of stereoisomers thereof.

9. (Currently Amended) The compound of Claim 8 in which:

~~X³ is cyano, C(O)X⁴, C(O)H, C(O)N(CH₃)OCH₃, CH(OCH₃)₂, C(O)CF₃, C(O)CF₂CF₃, CH₂C(O)R¹⁶, (E)-2-benzenesulfonyl vinyl,~~

~~2-dimethylcarbamoyl 2,2-difluoro-acetyl, 2-oxo-2-pyrrolidin-1-yl-acetyl, 2-morpholin-4-yl 2-oxo-acetyl, 2-oxo-2-piperazin-1-yl-acetyl, 2-(4-methanesulfonyl-piperazin-1-yl)-2-oxo-acetyl, 2-(1,1-dioxo-1 λ^6 -thiomorpholin-4-yl)-2-oxo-acetyl, dimethylaminooxalyl, tetrahydro-pyran-4-ylaminooxalyl, 2-morpholin-4-yl-ethylaminooxalyl, cyclopentyl-ethylaminooxalyl, pyridin-3-ylaminooxalyl, phenylaminooxalyl, 1-benzoyl-piperidin-4-ylaminooxalyl, 1-benzylcarbamoyl-methanoyl, 1-benzyloxy(oxalyl), 2-benzyloxy-acetyl, 2-benzenesulfonylamino-ethanoyl, 2-oxo-2-phenyl-ethanoyl, 3H-oxazole-2-carbonyl, 5-trifluoromethyl-oxazole-2-carbonyl, 3-trifluoromethyl-[1,2,4]oxadiazole-5-carbonyl, 2,2,3,3,3-pentafluoro-propionyl, hydroxyaminooxalyl, oxalyl, 2-(1,3-dihydro-isoindol-2-yl)-2-oxo-acetyl, benzothiazol-2-ylaminooxalyl, 2-oxo-ethyl, 2-oxazol-2-yl-2-oxo-ethyl or 2-benzooxazol-2-yl-2-oxo-ethyl;~~

~~X² is selected from OH, dimethylcarbamoyloxy, morpholin-4-ylcarbonyloxy, piperidin-1-yl-carbonyloxy, pyrrolidin-1-yl-carbonyloxy, pyrimidin-2-ylamino-, tetrahydro-pyran-4-ylamino, 1-methyl-piperidin-4-ylamino, N-(2-methoxyethyl)-N-(tetrahydro-pyran-4-yl)amino, isopropylamino and cyclohexylamino; 4-tert-butoxycarbonylpiperazin-1-ylcarbonyloxy, N-benzyl-carbamoyloxy, pyrrolidin-1-yl-carbonyloxy, N,N-dimethyl-carbamoyloxy, piperidin-1-yl-carbonyloxy, 4-methanesulfonyl-piperazin-1-yl-carbonyloxy, 4-ethoxycarbonylpiperazin-1-ylcarbonyloxy, N-cyclohexyl-carbamoyloxy, N-phenyl-carbamoyloxy, N-(5,6,7,8-tetrahydro-naphthalen-1-yl)-carbamoyloxy, N-butyl-N-methyl-carbamoyloxy, N-pyridin-3-yl-carbamoyloxy, N-isopropyl-carbamoyloxy, N-pyridin-4-yl-carbamoyloxy, N-cyanomethyl-N-methyl-carbamoyloxy, N,N-bis-(2-methoxy-ethyl)-carbamoyloxy, N-phenethyl-carbamoyloxy, piperazine-carbonyloxy, N-naphthalen-2-yl-carbamoyloxy, 4-benzyl-piperazine-1-carbamoyloxy, 4-(1-furan-2-yl-carbonyl)-piperazine-1-carbamoyloxy, thiomorpholin-4-yl-carbonyloxy, 1,1-dioxo-1 λ^6 -thiomorpholin-4-yl)-carbonyloxy, bis-(2-methoxy-ethyl)-carbamoyloxy, morpholin-4-ylcarbonyloxy, 2-methoxyethylcarbamoyloxy, diethylcarbamoyloxy, pyrrolidin-1-ylcarbonyloxy, 2-hydroxyethylcarbamoyloxy, tetrahydro-furan-2-ylmethylcarbamoyloxy,~~

~~cyclopropylcarbamoyloxy, *tert*-butylcarbamoyloxy, 3-hydroxy-pyrrolidin-1-yl-~~
~~carbonyloxy and carbamoyloxy; and~~

R³ is ~~thiophene-2-sulfonyl-methyl~~, 3-chloro-2-fluoro-phenyl-methane-sulfonyl-methyl,
benzene-sulfonyl-methyl, phenyl-methane-sulfonyl-methyl,
2-(1,1-difluoro-methoxy)-phenyl-methane-sulfonyl-methyl, 2-benzene-sulfonyl-ethyl,
2-(pyridine-2-sulfonyl)-ethyl, 2-(pyridine-4-sulfonyl)-ethyl, 2-phenyl-
methanesulfonyl-ethyl, oxy-pyridin-2-yl-methane-sulfonyl-methyl, prop-2-ene-1-sulfonyl-
methyl, 4-methoxy-phenyl-methane-sulfonyl-methyl, *p*-tolyl-methane-sulfonyl-methyl,
4-chloro-phenyl-methane-sulfonyl-methyl, *o*-tolyl-methane-sulfonyl-methyl,
3,5-dimethyl-phenyl-methane-sulfonyl-methyl, 4-trifluoro-methyl-phenyl-methane-
sulfonyl-methyl, 4-trifluoro-methoxy-phenyl-methane-sulfonyl-methyl, 2-bromo-phenyl-
methane-sulfonyl-methyl, ~~pyridin-2-yl-methane-sulfonyl-methyl~~, ~~pyridin-3-yl-methane-~~
~~sulfonyl-methyl~~, ~~pyridin-4-yl-methane-sulfonyl-methyl~~, naphthalen-2-yl-methane-
sulfonyl-methyl, 3-methyl-phenyl-methane-sulfonyl-methyl, 3-trifluoro-methyl-phenyl-
methane-sulfonyl-methyl, 3-trifluoro-methoxy-phenyl-methane-sulfonyl-methyl,
4-fluoro-2-trifluoromethoxy-phenyl-methane-sulfonylmethyl,
2-fluoro-6-trifluoromethyl-phenylmethanesulfonylmethyl,
3-chloro-phenylmethanesulfonylmethyl, 2-fluoro-phenylmethanesulfonylmethyl,
2-trifluoro-phenylmethanesulfonylmethyl, 2-cyano-phenylmethanesulfonylmethyl,
4-*tert*-butyl-phenylmethanesulfonylmethyl, 2-fluoro-3-methyl-phenyl-methane-sulfonyl-
methyl, 3-fluoro-phenylmethanesulfonylmethyl, 4-fluoro-phenylmethane-sulfonylmethyl,
2-chloro-phenylmethanesulfonylmethyl, 2,5-difluoro-phenylmethane-sulfonylmethyl,
2,6-difluoro-phenylmethanesulfonylmethyl, 2,5-dichloro-phenyl-methane-sulfonylmethyl,
3,4-dichloro-phenylmethanesulfonylmethyl, 2-(1,1-difluoro-methoxy)-phenyl-
methanesulfonylmethyl, 2-cyano-phenyl-methane-sulfonyl-methyl,
3-cyano-phenylmethanesulfonylmethyl, 2-trifluoro-methoxy-phenyl-methane-
sulfonylmethyl, 2,3-difluoro-phenylmethanesulfonylmethyl, 2,5-difluoro-phenyl-
methanesulfonylmethyl, biphenyl-2-ylmethanesulfonylmethyl, ~~cyclohexylmethyl~~,

3-fluoro-phenyl-methanesulfonylmethyl, 3,4-difluoro-phenyl-methanesulfonylmethyl, 2,4-difluoro-phenylmethanesulfonylmethyl, 2,4,6-trifluoro-phenylmethanesulfonylmethyl, 2,4,5-trifluoro-phenylmethanesulfonylmethyl, 2,3,4-trifluoro-phenylmethanesulfonylmethyl, 2,3,5-trifluoro-phenyl-methanesulfonylmethyl, 2,5,6-trifluoro-phenylmethanesulfonylmethyl, 2-chloro-5-trifluoro-methylphenylmethanesulfonylmethyl, ~~2-methyl-propane-1-sulfonyl~~, 2-fluoro-3-trifluoro-methylphenylmethanesulfonylmethyl, 2-fluoro-4-trifluoro-methylphenylmethanesulfonylmethyl, 2-fluoro-5-trifluoro-methyl-phenyl-methanesulfonyl-methyl, 4-fluoro-3-trifluoro-methylphenylmethanesulfonylmethyl, 2-methoxy-phenyl-methanesulfonylmethyl, 3,5-bis-trifluoromethyl-phenylmethanesulfonylmethyl, 4-difluoromethoxy-phenylmethanesulfonylmethyl, 2-difluoro-methoxy-phenyl-methanesulfonylmethyl, 3-difluoromethoxy-phenylmethanesulfonylmethyl, 2,6-dichloro-phenylmethanesulfonylmethyl, biphenyl-4-ylmethanesulfonylmethyl, ~~3,5-dimethyl-isoxazol-4-ylmethanesulfonylmethyl~~, ~~5-chloro-thien-2-yl-methanesulfonylmethyl~~, 2-[4-(1,1-difluoro-methoxy)-benzenesulfonyl]-ethyl, 2-[2-(1,1-difluoro-methoxy)-benzenesulfonyl]-ethyl, 2-[3-(1,1-difluoro-methoxy)-benzenesulfonyl]-ethyl, 2-(4-trifluoromethoxy-benzenesulfonyl)-ethyl, 2-(3-trifluoromethoxy-benzenesulfonyl)-ethyl, 2-(2-trifluoro-methoxy-benzene-sulfonyl)-ethyl, ~~(cyanomethyl-methyl-carbamoyl)-methyl~~, ~~biphenyl-3-ylmethyl~~, ~~2-oxo-2-pyrrolidin-1-yl-ethyl~~, 2-benzenesulfonyl-ethyl, ~~isobutylsulfanylmethyl~~, ~~2-phenylsulfanyl-ethyl~~, cyclohexylmethanesulfonylmethyl, 2-cyclohexyl-ethanesulfonyl, ~~benzyl~~, ~~naphthalen-2-yl~~, benzylsulfanylmethyl, 2-trifluoromethyl-benzylsulfanylmethyl, phenylsulfanyl-ethyl, cyclopropyl-methanesulfonylmethyl, ~~5-bromo-thien-2-ylmethyl~~, ~~3-phenyl-propyl~~, ~~2,2-difluoro-3-phenyl-propyl~~, 3,4,5-trimethoxy-phenylmethanesulfonylmethyl, ~~2,2-difluoro-3-thien-2-yl-propyl~~, ~~cyclohexylethyl~~, ~~cyclohexylmethyl~~, ~~tert-butylmethyl~~, ~~1-methyleyclohexylmethyl~~, ~~1-methyleyclopentylmethyl~~, ~~2,2-difluoro-3-phenylpropyl~~, ~~2,2-dimethyl-3-phenylpropyl~~, ~~1-benzyleyclopropylmethyl~~, $-X^5S(O)_2R^{13}$ and $-X^5S(O)_2R^{14}$, wherein R^{13} is alkyl and R^{14} is

phenyl which phenyl is unsubstituted or substituted; and the pharmaceutically acceptable salts and solvates of such compounds and the *N*-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and mixtures of stereoisomers thereof.

10. (Currently Amended) A compound of Claim 9 in which:

~~X³ is 1*H*-benzoimidazol-2-ylcarbonyl, pyrimidin-2-ylcarbonyl, benzooxazol-2-ylcarbonyl, benzothiazol-2-ylcarbonyl, pyridazin-3-ylcarbonyl, 3-phenyl-[1,2,4]oxadiazol-5-ylcarbonyl or 3-ethyl-[1,2,4]oxadiazol-5-ylcarbonyl, 2-oxo-2-pyrrolidin-1-yl-acetyl, 2-morpholin-4-yl-2-oxo-acetyl, 2-oxo-2-piperazin-1-yl-acetyl, 2-(4-methanesulfonyl-piperazin-1-yl)-2-oxo-acetyl, 2-(1,1-dioxo-1-thiomorpholin-4-yl)-2-oxo-acetyl, dimethylaminooxalyl, tetrahydro-pyran-4-ylaminooxalyl, 2-morpholin-4-yl-ethylaminooxalyl, cyclopentyl-ethyl-aminooxalyl, pyridin-3-ylaminooxalyl, phenylaminooxalyl or 1-benzoyl-piperidin-4-ylaminooxalyl;~~

~~X² is selected from OH, dimethylcarbamoxyloxy, morpholin-4-ylcarbonyloxy, piperidin-1-yl-carbonyloxy, pyrrolidin-1-yl-carbonyloxy, pyrimidin-2-ylamino, tetrahydro-pyran-4-ylamino, 1-methyl-piperidin-4-ylamino, *N*-(2-methoxyethyl)-*N*-(tetrahydro-pyran-4-yl)amino, isopropylamino and cyclohexylamino;~~

~~R³ is cyclohexylethyl, cyclohexylmethyl, *tert*-butylmethyl, 1-methylcyclohexylmethyl, 1-methylcyclopentylmethyl, 2,2-difluoro-3-phenylpropyl, 2,2-dimethyl-3-phenylpropyl, 1-benzylcyclopropylmethyl, X⁵S(O)₂R¹³ or -X⁵S(O)₂R¹⁴, wherein R¹³ is alkyl and R¹⁴ is phenyl which phenyl is unsubstituted or substituted; and the pharmaceutically acceptable salts and solvates of such compounds and the *N*-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and mixtures of stereoisomers thereof.~~

11-13. (Cancelled).

14. (Currently Amended) A compound of Claim 1 selected from the group consisting of:

~~(R) N-cyanomethyl 2-hydroxy 3-phenylmethanesulfonyl-propionamide;~~

~~(R) N-(1-cyano-1-thiophen-2-yl-methyl) 2-hydroxy 3-phenylmethanesulfonyl-propionamide;~~

~~(R) N-(1-cyano-1-thiophen-2-yl-methyl) 3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propionamide;~~

~~(R) N-cyanomethyl 3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propionamide;~~

~~morpholine-4-carboxylic acid (R)-1-(cyanomethyl-carbamoyl)-2-phenylmethanesulfonyl-ethyl-ester;~~

~~morpholine-4-carboxylic acid (R)-1-(cyanomethyl-carbamoyl)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl-ester;~~

~~(R)-(2-methoxy-ethyl)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-phenylmethanesulfonyl-ethyl-ester;~~

~~(S)-diethyl-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl-ester;~~

~~(S)-pyrrolidine-1-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl-ester;~~

~~(S)-morpholine-4-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl-ester;~~

~~(S)-4-Ethyl-piperazine-1-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl-ester;~~

~~(S)-2-hydroxymethyl-pyrrolidine-1-carboxylic acid (S)-1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl-ester;~~

~~(S)-(2,2,2-Trifluoro-ethyl)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl-ester;~~

~~(S)-(2-hydroxyethyl)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl-ester;~~

~~(Tetrahydrofuran-2-ylmethyl)-carbamic acid (S)-1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;~~
~~(S)-Azetidine-1-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;~~
~~(S)-cyclopropyl-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;~~
~~(S)-piperidine-1-carboxylic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;~~
~~(S)-(2-methoxy-ethyl)-carbamic acid 1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;~~
~~(R)-3-hydroxy-pyrrolidine-1-carboxylic acid (S)-1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;~~
~~(S)-3-hydroxy-pyrrolidine-1-carboxylic acid (S)-1-(cyanomethyl-carbamoyl)-2-cyclohexyl-ethyl ester;~~
~~(S)-morpholine-4-carboxylic acid 1-(cyanomethyl-carbamoyl)-3-cyclohexyl-propyl ester;~~
morpholine-4-carboxylic acid (R)-1-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester; and
morpholine-4-carboxylic acid (R)-1-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propylcarbamoyl]-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl ester;
~~morpholine-4-carboxylic acid (R)-1-[(S)-1-(1-benzothiazol-2-yl-methanoyl)-propylcarbamoyl]-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-ethyl ester;~~
~~pyrrolidine-1-carboxylic acid (R)-1-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;~~
~~dimethyl-carbamic acid (R)-1-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;~~
~~morpholine-4-carboxylic acid (R)-1-[(S)-1-(1-benzylearbamoyl-methanoyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;~~
morpholine-4-carboxylic acid (S)-1-[(S)-1-(oxazolo[4,5-b]pyridine-2-carbonyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;

~~morpholine-4-carboxylic acid (S)-1-[(S)-1-(5-ethyl-[1,3,4]oxadiazole-2-carbonyl)-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl ester;~~

~~(S)-2-[(R)-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propanoylamino]-N-methoxy-N-methyl-butamide;~~

~~(R)-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-N-((S)-1-formyl-propyl)-2-hydroxy-propionamide;~~

~~(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-2-hydroxy-3-phenyl-methanesulfonyl-propionamide;~~

~~(S)-3-[3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-propanoylamino]-2-oxo-pentanoic acid-benzylamide;~~

~~N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-propionamide;~~

~~N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-3-phenyl-propyl]-3-p-tolylmethanesulfonyl-propionamide;~~

~~3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-(1-ethyl-2,3-dioxo-3-pyrrolidin-1-yl-propyl)-propionamide;~~

~~3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-(1-ethyl-3-morpholin-4-yl-2,3-dioxo-propyl)-propionamide;~~

~~3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-(1-ethyl-2,3-dioxo-3-piperazin-1-yl-propyl)-propionamide;~~

~~3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-[3-(1,1-dioxo-116-thiomorpholin-4-yl)-1-ethyl-2,3-dioxo-propyl]-propionamide;~~

~~3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-[1-ethyl-3-(4-methyl-sulfonyl-piperazin-1-yl)-2,3-dioxo-propyl]-propionamide;~~

~~3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-dimethylamide;~~

~~3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-cyclopentyl-ethyl-amide;~~

~~3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-phenylamide;~~

~~3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-pyridin-3-ylamide;~~

~~3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-(tetrahydro-pyran-4-yl)-amide;~~

~~3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-(1-benzoyl-piperidin-4-yl)-amide;~~

~~3-[3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionylamino]-2-oxo-pentanoic acid-(2-morpholin-4-yl-ethyl)-amide;~~

~~(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-2-(2-nitro-phenylamino)-3-phenylmethanesulfonyl-propionamide;~~

~~N-[1-(benzooxazole-2-carbonyl)-propyl]-3-phenylmethanesulfonyl-2-(pyrimidin-2-ylamino)-propionamide.~~

~~(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-butyl]-2-(5-nitro-thiazol-2-ylamino)-3-phenylmethanesulfonyl-propionamide;~~

~~(2S)-(4,4-difluoro-2-hydroxy-5-phenyl-pentanoic acid (1(S)-cyano-3-phenyl-propyl)-amide;~~

~~N-(1(S)-cyano-3-phenyl-propyl)-2-(S)-(2-morpholin-4-yl-2-oxo-ethoxy)-4-phenyl-butyramide;~~

~~N-(1-(S)-cyano-3-phenyl-propyl)-2-(S)-fluoro-4-phenyl-butyramide;~~

~~N-(1-(S)-cyano-3-phenyl-propyl)-2,2-difluoro-4-phenyl-butyramide;~~

~~N-(1-(S)-cyano-3-phenyl-propyl)-2-(S)-hydroxy-4-phenyl-butyramide;~~

~~N (1 (S) cyano 3 phenyl propyl) 2 (R) hydroxy 4 phenyl butyramide;~~
~~N (1 (S) cyano 3 phenyl propyl) 2 (R) methoxy 4 phenyl butyramide;~~
~~2,2 difluoro 5 phenyl pentanoic acid (1 cyano cyclopropyl) amide;~~
~~N (1 (S) cyano 3 phenyl propyl) 4 phenyl butyramide;~~
~~2,2 difluoro 5 phenyl pentanoic acid ((S) 1 cyano 3 phenyl propyl) amide;~~
~~N (4 cyano 1 ethyl piperidin 4 yl) 3 cyclohexyl propionamide;~~
~~N (4 cyano 1 ethyl piperidin 4 yl) 3 (2 difluoromethoxy phenylmethanesulfonyl)-~~
~~propionamide;~~
~~(S) tert butyl carbamic acid 1 (cyanomethyl carbamoyl) 2 cyclohexyl ethyl ester;~~
~~(R) carbamic acid 1 (cyanomethyl carbamoyl) 2 (2 difluoromethoxy-~~
~~phenylmethanesulfonyl) ethyl ester;~~
~~(S) carbamic acid 1 (cyanomethyl carbamoyl) 2 cyclohexyl ethyl ester;~~
~~(R) morpholine 4 carboxylic acid 1 (1 cyano cyclopropyl carbamoyl) 2-~~
~~phenylmethanesulfonyl ethyl ester;~~
~~(R) morpholine 4 carboxylic acid 1 (4 cyano tetrahydro pyran 4 yl carbamoyl) 2-~~
~~phenylmethanesulfonyl ethyl ester;~~
~~3 cyclohexyl 2 hydroxy N [1 (oxazolo[4,5-*b*]pyridine 2 carbonyl) propyl] propionamide;~~
~~(R) N [1 (benzothiazole 2 carbonyl) butyl] 2 isopropylamino 3-~~
~~phenylmethanesulfonyl propionamide;~~
~~(R) N [1 (benzothiazole 2 carbonyl) butyl] 3 phenylmethanesulfonyl 2-~~
~~(tetrahydro pyran 4 yl amino) propionamide;~~
~~(R) N [1 (benzothiazole 2 carbonyl) butyl] 2 dibenzylamino 3-~~
~~phenylmethanesulfonyl propionamide;~~
~~(R) N [1 (benzothiazole 2 carbonyl) butyl] 2 dimethylamino 3-~~
~~phenylmethanesulfonyl propionamide;~~
~~(R) N [(S) 1 (benzoxazole 2 carbonyl) butyl] 3 phenylmethanesulfonyl 2-~~
~~(tetrahydro pyran 4 yl amino) propionamide;~~

~~(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-(1-methyl-piperidin-4-ylamino)-3-phenylmethanesulfonyl-propionamide;~~

~~(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-(bis-thiophen-2-ylmethyl-amino)-3-phenylmethanesulfonyl-propionamide;~~

~~(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-dibenzylamino-3-phenylmethanesulfonyl-propionamide;~~

~~(S)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-(tetrahydro-pyran-4-ylamino)-3-thiophen-2-yl-propionamide;~~

~~(S)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-isopropylamino-3-thiophen-2-yl-propionamide;~~

~~(R)-N-[1-(benzothiazole-2-carbonyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~

~~(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~

~~(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-isopropylamino-3-phenylmethanesulfonyl-propionamide;~~

~~(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-[(2-methoxy-ethyl)-(tetrahydro-pyran-4-yl)-amino]-3-phenylmethanesulfonyl-propionamide;~~

~~(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-cyclohexylamino-3-phenylmethanesulfonyl-propionamide;~~

~~(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-2-dimethylamino-3-phenylmethanesulfonyl-propionamide;~~

~~(1S)-N-[1-(benzoxazole-2-carbonyl)-butyl]-2-(S)-fluoro-4-phenyl-butyramide;~~

~~2,2-difluoro-5-phenyl-pentanoic acid [(S)-1-(benzoxazole-2-carbonyl)-butyl]-amide;~~

~~morpholine-4-carboxylic acid (S)-1-[(S)-1-(benzoxazole-2-carbonyl)-propylcarbamoyl]-2-cyclohexyl-ethyl ester;~~

~~morpholine-4-carboxylic acid (S)-2-cyclohexyl-1-[(S)-1-(oxazolo[4,5-b]pyridine-2-carbonyl)-propylcarbamoyl]-ethyl ester;~~

~~morpholine-4-carboxylic acid (S)-2-cyclohexyl-1-[(S)-1-(5-ethyl-[1,3,4]oxadiazole-2-carbonyl)-propylcarbamoyl]-ethyl ester;~~

~~morpholine-4-carboxylic acid (S)-2-cyclohexyl-1-[(S)-1-(5-phenyl-[1,3,4]oxadiazole-2-carbonyl)-propylcarbamoyl]-ethyl ester;~~

~~morpholine-4-carboxylic acid (S)-1-[(S)-1-(benzoxazole-2-carbonyl)-propylcarbamoyl]-3-cyclohexyl-propyl ester;~~

~~4-[4,4-dimethyl-2-(morpholine-4-carbonyloxy)-pentanoylamino]-3-oxo-azepane-1-carboxylic acid benzyl ester;~~

~~-(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-butyl]-3-cyclopropylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~

~~-(R)-N-[1-(benzoxazole-2-carbonyl)-butyl]-2-cyclohexylamino-3-cyclopropylmethanesulfonyl-propionamide;~~

~~(R)-N-[1-(benzoxazole-2-carbonyl)-butyl]-2-cycloheptylamino-3-cyclopropylmethanesulfonyl-propionamide;~~

~~(R)-3-phenylmethanesulfonyl-N-[(S)-3-phenyl-1-(thiazole-2-carbonyl)-propyl]-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~

~~(R)-N-[(S)-1-(benzoxazole-2-carbonyl)-3-phenyl-propyl]-3-cyclopropylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~

~~(R)-3-cyclopropylmethanesulfonyl-N-[1-(5-ethyl-1,2,4-oxadiazole-3-carbonyl)-propyl]-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~

~~(R)-3-phenylmethanesulfonyl-N-[1-(3-phenyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~

~~(R)-N-[1-(3-cyclopropyl-1,2,4-oxadiazole-5-carbonyl)-propyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~

~~{(R)-1-[1-(benzothiazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~{{(S)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-thiophen-2-yl-ethyl}-carbamic acid tert-butyl ester;~~

~~{{(R)-1-[1-(benzothiazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~{{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~{{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-cyclopropylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~((R)-1-[1-[hydroxy-(3-phenyl-1,2,4-oxadiazol-5-yl)-methyl]-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl)-carbamic acid tert-butyl ester;~~

~~((R)-2-cyclopropylmethanesulfonyl-1-[(S)-1-[(5-ethyl-1,2,4-oxadiazol-3-yl)-hydroxy-methyl]-propylcarbamoyl]-ethyl)-carbamic acid tert-butyl ester;~~

~~{{(R)-1-[1-(benzoxazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~{{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-3-phenyl-propylcarbamoyl]-2-cyclopropylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~{{(R)-1-[(S)-1-(hydroxy-thiazol-2-yl-methyl)-3-phenyl-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~{{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-cyclopropylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~((R)-1-[1-[hydroxy-(3-phenyl-1,2,4-oxadiazol-5-yl)-methyl]-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl)-carbamic acid tert-butyl ester;~~

~~((R)-2-cyclopropylmethanesulfonyl-1-[(S)-1-[(5-ethyl-1,2,4-oxadiazol-3-yl)-hydroxy-methyl]-propylcarbamoyl]-ethyl)-carbamic acid tert-butyl ester;~~

~~{{(R)-1-[1-(benzoxazol-2-yl-hydroxy-methyl)-butylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~{{(R)-1-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-3-phenyl-propylcarbamoyl]-2-cyclopropylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~

~~{(R)-1-[(S)-1-(hydroxy-thiazol-2-yl-methyl)-3-phenyl-propylcarbamoyl]-2-phenylmethanesulfonyl-ethyl}-carbamic acid tert-butyl ester;~~
~~(R)-2-phenylmethanesulfonyl-1-[(S)-1-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-hydroxy-methyl]-propylcarbamoyl]-ethyl)-carbamic acid tert-butyl ester;~~
~~(R)-N-[1-(Benzoxazol-2-carbonyl)-butyl]-2-[cyclopropylmethyl-(tetrahydro-pyran-4-ylmethyl)-amino]-3-phenylmethanesulfonyl-propionamide;~~
~~(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-2-dibenzylamino-3-phenylmethanesulfonyl-propionamide;~~
~~(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~
~~(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-2-isopropylamino-3-phenylmethanesulfonyl-propionamide;~~
~~(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-2-dimethylamino-3-phenylmethanesulfonyl-propionamide;~~
~~(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~
~~(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-(1-methyl-piperidin-4-ylamino)-3-phenylmethanesulfonyl-propionamide;~~
~~(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-(bis-thiophen-2-ylmethyl-amino)-3-phenylmethanesulfonyl-propionamide;~~
~~(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-dibenzylamino-3-phenylmethanesulfonyl-propionamide;~~
~~(S)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-(tetrahydro-pyran-4-ylamino)-3-thiophen-2-yl-propionamide;~~
~~S)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-isopropylamino-3-thiophen-2-yl-propionamide;~~
~~(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-isopropylamino-3-phenylmethanesulfonyl-propionamide;~~

~~(R)-N-[1-(benzothiazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~
~~R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~
~~(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-3-phenylmethanesulfonyl-2-(tetrahydro-pyran-4-ylamino)-propionamide;~~
~~(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-[(2-methoxy-ethyl)-(tetrahydro-pyran-4-yl)-amino]-3-phenylmethanesulfonyl-propionamide;~~
~~(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-cyclohexylamino-3-phenylmethanesulfonyl-propionamide;~~
~~(R)-N-[(S)-1-(benzoxazol-2-yl-hydroxy-methyl)-butyl]-2-dimethylamino-3-phenylmethanesulfonyl-propionamide;~~
~~N-cyanomethyl-3-cyclohexyl-propionamide;~~
~~N-cyanomethyl-3-(2-difluoromethoxy-phenylmethanesulfonyl)-propionamide;~~
~~3-(3-cyclohexyl-propionylamino)-2-oxo-5-phenyl-pentanoic acid-thiazol-2-ylamide;~~
~~3-cyclohexyl-N-(1-formyl-3-phenyl-propyl)-propionamide;~~
~~3-(2-difluoromethoxy-phenylmethanesulfonyl)-N-[(S)-1-(5-ethyl-[1,3,4]oxadiazole-2-carbonyl)-propyl]-propionamide;~~
~~N-[(S)-1-(benzooxazole-2-carbonyl)-propyl]-2-(2-cyano-phenylamino)-3-cyclohexyl-propionamide;~~
~~N-Cyanomethyl-3-cyclohexyl-2-(4-methoxy-phenoxy)-propionamide;~~
~~2-benzyloxy-N-cyanomethyl-3-cyclohexyl-propionamide;~~
~~(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-butyl]-2-benzyloxy-3-phenylmethanesulfonyl-propionamide;~~
~~(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-2-methoxymethoxy-3-phenylmethanesulfonyl-propionamide;~~
~~(S)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-butyl]-2-hydroxy-3-phenyl-propionamide;~~

~~(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-3-phenylmethanesulfonyl-2-triisopropylsilanyloxy-propionamide;~~

~~(R)-N-[(S)-1-(1-benzothiazol-2-yl-methanoyl)-propyl]-2-hydroxy-3-phenylmethanesulfonyl-propionamide;~~

~~(R)-2-hydroxy-3-phenylmethanesulfonyl-N-[(S)-1-(1-pyridazin-3-yl-methanoyl)-butyl]-propionamide;~~

~~(S)-3-((R)-2-hydroxy-3-phenylmethanesulfonyl-propanoylamino)-2-oxo-pentanoic acid-benzylamide;~~

~~(R)-N-[(S)-1-(1-benzooxazol-2-yl-methanoyl)-propyl]-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propionamide;~~

~~(R)-N-[(S)-1-(1-benzothiazol-2-yl-methanoyl)-propyl]-3-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonyl]-2-hydroxy-propionamide;~~

~~(2R,5S)-2-[2-(1,1-difluoro-methoxy)-phenylmethanesulfonylmethyl]-6-ethoxy-5-ethyl-morpholin-3-one; or their corresponding N-oxides, and their prodrugs, and their protected derivatives, individual isomers and mixtures of isomers thereof; and the pharmaceutically-acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and their prodrugs, and their protected derivatives, individual isomers and mixtures of isomers thereof. and the pharmaceutically acceptable salts and solvates of such compounds and the N-oxides, prodrugs, compounds thereof having protected reactive groups, stereoisomers and mixtures of stereoisomers thereof.~~

15-16. (Cancelled)

17. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

18. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 2 in combination with a pharmaceutically acceptable excipient.

19-20. (Cancelled)